Author: KEI Staff

Below are asks from the 2010 PhRMA submission to the USTR Special 301 list on the topic of drug pricing and reimbursement decisions, and described as ‘Market Access Barriers.’ In its assertions, PhRMA attack countries for government price negotiations, making use of reference pricing, the insufficient involvement of pharmaceutical companies in setting government pricing policies and the composition of drug formularies, among other things.

CHINA

Continue Reading →

Billy Tauzin announced today that he will be stepping down as President and CEO of the Pharmaceutical Research and Manufacturers of America (PhRMA) at the end of June 2010.

PhRMA’s 990 Tax Return Form, Schedule J-1 shows the amount Tauzin was compensated in 2008:

Base compensation: $2,055,445
Bonus & incentive compensation: $692,875
Other reportable compensation: $159,412
Deferred compensation: $1,556,960
Nontaxable benefits: $11,465

Total: $4,476,157
Continue Reading →

In the United States, tax exempt non-profit organizations are subject some some requirements for financial disclosure via the IRS form 990, which is available to the public. The disclosure requirements cover most U.S. based trade associations, including the Pharmaceutical Research and Manufacturers of America (PhRMA), the trade association for some 28 “member” companies.

Continue Reading →

At the end of a dramatic debate that began yesterday, the Executive Board (EB) of the World Health Organization (WHO) agreed to hold a special consultation on the report of the WHO Expert Working Group (EWG) on R&D Financing. A face-to-face meeting will be held on May 13, a few days before the 63rd WHA begins on 17 May. There will also be opportunities for web submissions on the EWG report. In addition, Dr. Continue Reading →

Using the U.S. Freedom of Information Act (FOIA), KEI has obtained the daily schedule of Ambassador Kirk, from March 20 to May 1, 2009. KEI has separately asked the USTR to routinely as a matter of transparency post this information on the USTR web page.

The response to the follow is presented below in two pdf files:
March 20 to April 14, 2009
April 15 to May 1, 2009

Continue Reading →